Efficacy and safety of up to two years of tralokinumab treatment in adults of different racial subgroups with moderate-to-severe atopic dermatitis

Main Article Content

Tiffany Mayo
University of Alabama at Birmingham, Birmingham, AL, USA

April Armstrong
Keck School of Medicine of University of Southern California, Los Angeles, CA, USA

Leon Kircik
Icahn School of Medicine at Mount Sinai, New York, NY, USA

Jonathan Silverberg
The George Washington School of Medicine and Health Sciences, Washington, DC, USA

Andrew Blauvelt
Oregon Medical Research Center, Portland, OR, USA

Ben Esdaile
Whittington Health National Health Service Foundation Trust, London, UK

Shannon Schneider
LEO Pharma Inc., Madison, NJ, USA

Thomas Mark
LEO Pharma A/S, Ballerup, Denmark

Melinda Gooderham
SKiN Centre for Dermatology, Peterborough, ON, Canada

Andrew Alexis
Weill Cornell Medicine, New York, NY, USA

Keywords

atopic dermatitis, tralokinumab

References

1. Weidinger S, Novak N. Lancet. 2016;387(10023):1109-1122.

2. Kaufman B, et al. Exp Dermatol 2018; 27: 340-357.

3. Blauvelt A, et al. J Am Acad Dermatol. 2022;S0190-9622(22)02345-3.

Article Sidebar

Poster PDF
Published
Mar 13, 2023
DOI https://doi.org/10.25251/skin.7.supp.144

Article Details

How to Cite
Mayo, T., Armstrong, A., Kircik, L., Silverberg, J., Blauvelt, A., Esdaile, B., Schneider, S., Mark, T., Gooderham, M., & Alexis, A. (2023). Efficacy and safety of up to two years of tralokinumab treatment in adults of different racial subgroups with moderate-to-severe atopic dermatitis. SKIN The Journal of Cutaneous Medicine, 7(2), s144. https://doi.org/10.25251/skin.7.supp.144
Issue
Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®
Section
Atopic Dermatitis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Similar Articles

1 2 3 4 5 > >> 

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>